Skip to main content
Premium Trial:

Request an Annual Quote

Dutch Toxicogenomics Center to Use GeneGo for Chemical Studies

NEW YORK (GenomeWeb News) – GeneGo said today it will collaborate with The Netherlands Toxicogenomics Center on a project aimed at developing predictive screens that could evaluate the safety of chemicals for humans and could be used as replacements or refinements to some animal studies.
The NTC will use GeneGo’s MetaCore and MetaDrug data analysis software to manage and interpret data from proteomic, metabolomics, chemical, and gene expression research and to identify pathway functions that may contribute to adverse events caused by the introduction of foreign chemicals.
The company also will work with the NTC’s bioinformatics group to develop predictive models that could help identify adverse effects in animals from short-term in vivo experiments or from in vitro experiments in which cells are used instead of animals.
The company said the collaboration is part of a five year, multi-party project being funded with €25 million ($36.4 million).
Richard Brennan, director of toxicology at GeneGo, said the joint project will help the company “further validate and develop” its predictive systems toxicology capabilities.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.